Three Rivers expands rights to Infergen
This article was originally published in Scrip
Executive Summary
Three Rivers Pharmaceuticals has gained more commercial rights to Amgen's hepatitis C drug Infergen ((interferon alfacon-1). The definitive licence agreement signed with Amgen will give Three Rivers commercial rights to the drug in all markets except Japan and it will obtain commercial rights in China from March 31st, 2009. The company currently has commercial rights to Infergen in the US and Canada which it bought from Valeant Pharmaceuticals late last year (Scrip Online, December 21st, 2007). Three Rivers will seek marketing partners to help commercialise Infergen outside the US.
You may also be interested in...
Innovation not M&A to drive Bayer growth in LatAm
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
2010 Scrip 100 - Is Anvisa a friend of innovators?
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan raises $1.5 billion
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.